TY - JOUR
T1 - Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping
AU - Tai, Wei
AU - Gong, Sheryl L.
AU - Tsunoda, Shirley M.
AU - Greenberg, Howard E.
AU - Gorski, J. Christopher
AU - Penzak, Scott R.
AU - Stoch, S. Aubrey
AU - Ma, Joseph D.
PY - 2013/12/1
Y1 - 2013/12/1
N2 - Background: Midazolam apparent oral clearance (CLORAL) is used to estimate intestinal and hepatic cytochrome P450 (CYP) 3A activity. A limited sampling approach was performed to access a midazolam partial area under the concentration time curve (AUC) to estimate CLORAL. Methods: Midazolam plasma concentrations from healthy adults were obtained during CYP3A baseline (n = 116), inhibition (n = 75), and induction or activation (n = 66) from seven published studies. Observed CLORAL and partial AUCs of AUC 0-2, AUC0-4, AUC0-6, AUC1-2, AUC1-4, AUC2-4, and AUC2-6 were determined by noncompartmental analysis. Subject data were randomly divided into a training set and a validation set. Linear regression equations, derived from partial AUCs, were developed from training set data. Predicted CLORAL was determined from these equations from validation set data. Preset criterion was a coefficient of determination (r2) greater than or equal to 0.9. Bias and precision were evaluated by relative percent mean prediction error (%MPE) and relative percent mean absolute error (%MAE). Results: During CYP3A baseline conditions, all of the evaluated CL ORAL equations had unacceptable r2 (range: 0.34 0.86). During CYP3A inhibition, all of the evaluated CLORAL equations had unacceptable %MAE. Acceptable r2, %MPE, and %MAE were observed during CYP3A induction/activation with AUC0-4 (r2 = 0.99, %MPE = 3.9, %MAE = 12.5) and AUC1-4 (r2 = 0.99, %MPE = 6%, %MAE = 11.1%). The same equations also predicted the extent of CYP3A induction as a lack of equivalence was observed with AUC0-4 and AUC1-4. Conclusions: Midazolam partial AUCs were unable to estimate CYP3A activity during the evaluated baseline and inhibitory conditions. Midazolam CL ORAL utilizing a partial AUC0-4 and AUC1-4 was able to estimate CYP3A induction with rifampin and Ginkgo biloba extract.
AB - Background: Midazolam apparent oral clearance (CLORAL) is used to estimate intestinal and hepatic cytochrome P450 (CYP) 3A activity. A limited sampling approach was performed to access a midazolam partial area under the concentration time curve (AUC) to estimate CLORAL. Methods: Midazolam plasma concentrations from healthy adults were obtained during CYP3A baseline (n = 116), inhibition (n = 75), and induction or activation (n = 66) from seven published studies. Observed CLORAL and partial AUCs of AUC 0-2, AUC0-4, AUC0-6, AUC1-2, AUC1-4, AUC2-4, and AUC2-6 were determined by noncompartmental analysis. Subject data were randomly divided into a training set and a validation set. Linear regression equations, derived from partial AUCs, were developed from training set data. Predicted CLORAL was determined from these equations from validation set data. Preset criterion was a coefficient of determination (r2) greater than or equal to 0.9. Bias and precision were evaluated by relative percent mean prediction error (%MPE) and relative percent mean absolute error (%MAE). Results: During CYP3A baseline conditions, all of the evaluated CL ORAL equations had unacceptable r2 (range: 0.34 0.86). During CYP3A inhibition, all of the evaluated CLORAL equations had unacceptable %MAE. Acceptable r2, %MPE, and %MAE were observed during CYP3A induction/activation with AUC0-4 (r2 = 0.99, %MPE = 3.9, %MAE = 12.5) and AUC1-4 (r2 = 0.99, %MPE = 6%, %MAE = 11.1%). The same equations also predicted the extent of CYP3A induction as a lack of equivalence was observed with AUC0-4 and AUC1-4. Conclusions: Midazolam partial AUCs were unable to estimate CYP3A activity during the evaluated baseline and inhibitory conditions. Midazolam CL ORAL utilizing a partial AUC0-4 and AUC1-4 was able to estimate CYP3A induction with rifampin and Ginkgo biloba extract.
KW - cytochrome P450 3A (CYP3A)
KW - limited sampling
KW - midazolam
KW - partial AUC
KW - phenotyping
UR - http://www.scopus.com/inward/record.url?scp=84891409552&partnerID=8YFLogxK
U2 - 10.1515/dmdi-2013-0040
DO - 10.1515/dmdi-2013-0040
M3 - Article
C2 - 24114901
AN - SCOPUS:84891409552
SN - 0792-5077
VL - 28
SP - 217
EP - 223
JO - Drug Metabolism and Drug Interactions
JF - Drug Metabolism and Drug Interactions
IS - 4
ER -